智能自控公告，公司控股股东、实际控制人沈剑标一致行动人无锡天亿信投资有限公司于2025年11月11 日至2025年11月17日通过集中竞价累计减持202.01万股，占公司总股本0.57%，持股比例由36.45%降至 35.88%，权益变动触及1%整数倍。此前其计划在2025年11月10日至2026年2月8日期间减持不超过355万 股，占1.00%。 ...

格隆汇11月18日丨智能自控(002877.SZ)公布，公司近日收到控股股东、实际控制人之一致行动人无锡 天亿信投资有限公司的《关于股份减持计划实施情况的告知函》，无锡天亿信投资有限公司自2025年11 月11日至2025年11月17日通过集中竞价交易方式累计减持公司股份2,020,100股，占公司总股本的 0.57%。本次权益变动后，公司控股股东、实际控制人及一致行动人无锡天亿信投资有限公司合计持有 公司股份占公司总股本的比例由36.45%降至35.88%，权益变动触及1%的整数倍。 ...

证券代码：002877 证券简称：智能自控 公告编号：2025-074 无锡智能自控工程股份有限公司 关于使用暂时闲置募集资金进行现金管理进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 无锡智能自控工程股份有限公司（以下简称"公司"）2025 年 9 月 12 日召开的 第五届董事会第二十一次会议审议通过了《关于继续使用暂时闲置募集资金进行现 金管理的议案》，为提高公司募集资金的使用效率，公司拟在不影响募集资金使用的 情况下，根据募集资金投资项目的投资计划和建设进度，在确保资金安全的前提下， 根据《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》、《上市公司募集资金监管规则》等有关法律法规的 规定，使用不超过人民币 5,000 万元的暂时闲置募集资金进行现金管理，该额度在 董事会审议通过之日起十二个月内可循环滚动使用。《关于继续使用暂时闲置募集资 金进行现金管理的公告》（公告编号：2025-064）已于 2025 年 9 月 15 日刊登于《证 券时报》和巨潮资讯网（www.cninfo.co ...

Core Viewpoint - Intelligent Control (002877.SZ) reported its Q3 2025 results, indicating a decrease in institutional ownership compared to the previous quarter [1] Group 1: Institutional Ownership - As of October 27, 2025, there is one institutional investor holding shares in Intelligent Control, with a total holding of 5.0728 million shares, representing 1.43% of the total share capital [1] - The institutional ownership ratio has decreased by 0.63 percentage points compared to the previous quarter [1] Group 2: Public Fund Disclosure - In this reporting period, 24 public funds were not disclosed compared to the previous quarter, including funds such as Guojin Quantitative Multi-Factor A, Guojin Quantitative Selected A, and others [1]

Core Insights - The company reported a revenue of 798 million yuan for the first three quarters of 2025, representing a year-on-year growth of 1.65% [1] - The net profit attributable to shareholders decreased by 49.68% to 16.9477 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 55.53% to 14.2673 million yuan [1]

Group 1 - The core point of the article is that Intelligent Control (SZ 002877) reported its Q3 performance, showing a slight increase in revenue but a significant decline in net profit [1] - For the first three quarters of 2025, the company's revenue was approximately 798 million yuan, representing a year-on-year increase of 1.65% [1] - The net profit attributable to shareholders was about 16.95 million yuan, reflecting a year-on-year decrease of 49.68% [1] - The basic earnings per share were 0.048 yuan, down 49.47% compared to the previous year [1] Group 2 - As of the report, Intelligent Control's market capitalization stands at 3.2 billion yuan [2]

证券代码：002877 证券简称：智能自控 公告编号：2025-072 无锡智能自控工程股份有限公司 第五届董事会第二十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 无锡智能自控工程股份有限公司（以下简称"公司"）第五届董事会第二十三次 会议的通知于 2025 年 10 月 17 日以邮件、电子通讯等方式向全体董事发出。会议于 2025 年 10 月 24 日在公司 303 会议室召开。会议应到董事 7 名，实到董事 7 名，部 分高级管理人员列席了会议。会议由沈剑标先生主持。会议的召开符合有关法律、 法规及《公司章程》的规定。 二、董事会会议审议情况 （一）审议通过了《关于 2025 年第三季度报告的议案》 表决结果：7 票同意，0 票反对，0 票弃权。 本事项已经第五届董事会审计委员会第六次会议审议通过，审计委员会全体成 员同意该议案。 《2025 年第三季度报告》（公告编号 2025-073）详见公司指定信息披露媒体《证 券时报》及巨潮资讯网（www.cninfo.com.cn）公告。 三、备查文件 1、第五届 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥294,596,162.43, representing a year-on-year increase of 23.31%[5] - The net profit attributable to shareholders was a loss of ¥3,434,670.89, a decrease of 295.13% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥3,702,331.02, down 237.36% year-on-year[5] - The basic and diluted earnings per share were both -¥0.009, a decrease of 260.00% compared to the previous year[5] - Net profit for the current period was ¥16.95 million, down from ¥33.68 million in the previous period, indicating a decline of about 49.6%[19] - Basic and diluted earnings per share decreased to ¥0.048 from ¥0.095, a reduction of approximately 49.5%[20] - The company’s total profit for the current period was ¥17.44 million, a decrease from ¥37.70 million in the previous period, reflecting a decline of approximately 53.8%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,411,986,093.72, an increase of 1.21% from the end of the previous year[5] - The company's total assets amount to ¥2,411,986,093.72, an increase from ¥2,383,251,474.70 at the beginning of the period[16] - Current assets total ¥1,483,355,673.31, up from ¥1,415,443,344.81 at the start of the period[15] - Total liabilities stand at ¥1,199,255,805.40, a marginal increase from ¥1,198,699,319.49[16] - The company's equity attributable to shareholders increased to ¥1,212,730,288.32 from ¥1,184,552,155.21[16] Cash Flow - Cash flow from operating activities showed a net outflow of ¥30,513,453.39, an improvement of 73.70% compared to the previous period[10] - Cash flow from operating activities showed a net outflow of ¥30.51 million, an improvement compared to a net outflow of ¥116.04 million in the previous period[21] - Cash and cash equivalents at the end of the period totaled ¥43.92 million, down from ¥26.25 million in the previous period[22] - The company reported a net cash outflow from investment activities of ¥34.51 million, contrasting with a net inflow of ¥19.57 million in the previous period[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,658[11] - The largest shareholder, Shen Jianbiao, holds 35.02% of the shares, totaling 124,616,800 shares[11] - The company has no preferred shareholders or significant changes in shareholder financing activities reported[12] Operating Costs and Expenses - Total operating revenue for the current period reached ¥797.53 million, an increase from ¥784.58 million in the previous period, representing a growth of approximately 1.21%[18] - Total operating costs increased to ¥773.72 million from ¥740.48 million, marking a rise of about 4.48%[18] - Research and development expenses rose significantly to ¥40.71 million, up from ¥31.50 million, reflecting an increase of approximately 29.2%[19] Financial Activities - Financial expenses increased by 77.46% to ¥39,087,795.83, primarily due to one-time compensatory interest payments related to convertible bonds[10] - Short-term borrowings rose by 45.03% to ¥489,199,989.12, attributed to an increase in financing scale during the reporting period[9] - The company’s capital reserve increased by 34.07% to ¥234,297,427.32, mainly due to the conversion of unconverted portions of convertible bonds into capital reserves[9] - The company raised ¥665 million through financing activities, compared to ¥441.58 million in the previous period, an increase of approximately 50.7%[22] - The company reported a significant increase in prepayments by 143.83% to ¥26,778,641.06, mainly due to increased procurement prepayments[9]

Core Viewpoint - The company has received approval from the Guangzhou Intermediate People's Court to extend its pre-restructuring period until January 11, 2026, due to its inability to fulfill legal obligations and debts, despite having restructuring value and feasibility [1] Group 1 - The company was unable to fulfill effective legal documents and could not repay due debts, indicating a significant lack of solvency [1] - The pre-restructuring was initiated at the request of creditor Guangdong Jinglong Construction Group Co., Ltd. [1] - During the pre-restructuring period, the company will actively cooperate with the temporary administrator and the court, ensuring timely information disclosure [1]

Group 1 - Xuedilong plans to invest no more than 400 million yuan to build an innovation industrial base in Changping District, Beijing, focusing on chromatography and mass spectrometry production lines [1] - The project aims to enhance research and production capabilities in carbon monitoring and measurement systems [1] Group 2 - Zejing Pharmaceutical's tri-specific antibody drug ZGGS34 has received clinical trial approval from the National Medical Products Administration for treating MUC17 positive advanced solid tumors [2] - The drug shows strong anti-tumor activity and good safety in preclinical studies [2] Group 3 - Aosaikang's new cMET inhibitor ASK202 will present clinical research data at the 2025 ESMO annual meeting, showing an objective response rate of 68.8% and a disease control rate of 93.8% in advanced non-small cell lung cancer patients [2][3] Group 4 - China Life expects a net profit of 156.785 billion to 177.689 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 50% to 70% [4] Group 5 - Silan Microelectronics plans to jointly invest 5.1 billion yuan to build a 12-inch high-end analog chip production line, with a total project investment of 20 billion yuan [5][6] Group 6 - New City intends to use 156.65 million yuan of remaining fundraising to invest in a "Building Green Energy and Zero Carbon Park" project, with a total investment of 257 million yuan [8] Group 7 - Yidao Information plans to acquire control of Guangzhou Langguo Electronic Technology and Shenzhen Chengwei Information through a combination of share issuance and cash payment [9] Group 8 - Xiling Information's controlling shareholder has received a notice of lifting restrictions, allowing normal business operations to resume [10] Group 9 - Dongpeng Holdings' first batch of rock slab products has passed the highest level 5A quality inspection, becoming one of the first companies to meet the new national standard [11] Group 10 - Aonlikang's levofloxacin tablets have received approval from the National Medical Products Administration, classified as a chemical drug of category 4 [15] Group 11 - Haizheng Pharmaceutical's Taizhou factory has had its GMP non-compliance declaration revoked by the EU, confirming compliance with EU GMP requirements [17][18] Group 12 - Hongfuhan's shareholder plans to reduce its stake by up to 1.5% through various trading methods due to asset integration and funding needs [19] Group 13 - Purang Co. plans to establish a wholly-owned subsidiary in Hong Kong to enhance its international competitiveness and service levels [20] Group 14 - Tianhe Magnetic Materials' subsidiary has signed an investment agreement for a project worth 850 million yuan focused on high-performance rare earth permanent magnets [22] Group 15 - Xiangfenghua reported a 64.64% year-on-year decline in net profit for the first three quarters, despite an 8.16% increase in revenue [23] Group 16 - Darui Electronics reported a 26.84% year-on-year increase in net profit for the first three quarters, with total revenue growing by 28.59% [24] Group 17 - Xiangsheng Medical reported a 4.56% year-on-year decline in net profit for the first three quarters, despite a 41.95% increase in net profit for the third quarter [25]